Complimentary Technical Snapshots on TransEnterix and Three More Medical Supplies Stocks
Stock Research Monitor: WAT, WST, and EKSO
LONDON, UK / ACCESSWIRE / June 11, 2018 / If you want a free Stock Review on TRXC sign up now at www.wallstequities.com/registration. Today's attention is redirected to the Medical Instruments and Supplies space, which comprises companies that manufacture and sell medical devices, instrument systems, and reagents and consumables. Medical instrument companies generally offer below-average dividend yields when compared to the wider market. Pre-market this morning, WallStEquities.com monitors TransEnterix Inc. (NYSE AMER: TRXC), Waters Corp. (NYSE: WAT), West Pharmaceutical Services Inc. (NYSE: WST), and Ekso Bionics Holdings Inc. (NASDAQ: EKSO). All you have to do is sign up today for this free limited time offer by clicking the link below.
www.wallstequities.com/registration
TransEnterix
Morrisville, North Carolina headquartered TransEnterix Inc.'s stock finished last Friday's session 8.85% higher at $3.69. A total volume of 8.43 million shares was traded, which was above their three months average volume of 3.45 million shares. The Company's shares have surged 77.40% in the past month, 112.07% over the previous three months, and 658.95% over the past year. The stock is trading above its 50-day and 200-day moving averages by 61.02% and 84.72%, respectively. Additionally, shares of TransEnterix, which engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery, have a Relative Strength Index (RSI) of 66.86.
On May 29th, 2018, research firm Ladenburg Thalmann downgraded the Company's stock rating from 'Buy' to 'Neutral'.
On June 07th, 2018, TransEnterix announced that it filed a FDA 510(k) submission for additional Senhance System instruments, including 3-millimeter diameter instruments. The clearance of these instruments would allow the Senhance to be used for microlaparoscopic surgeries, allowing surgeons to make tiny incisions that are deemed virtually scarless for patients. Get the full research report on TRXC for free by clicking below at:
www.wallstequities.com/registration/?symbol=TRXC
Waters
On Friday, shares in Milford, Massachusetts headquartered Waters Corp. ended the session 1.15% higher at $205.32. The stock recorded a trading volume of 521,313 shares. The Company's shares have gained 6.17% in the last month and 10.19% over the past year. The stock is trading 4.40% above its 50-day moving average and 4.36% above its 200-day moving average. Moreover, shares of Waters, which provides analytical workflow solutions in the US, Europe, Asia, and internationally, have an RSI of 67.44.
On June 06th, 2018, Waters Corp. announced that Chris O'Connell, Chairman and CEO, will speak to the investment community at the William Blair 38th Annual Growth Stock Conference to be held on June 13th, 2018, at 10:40 a.m. CT at the Four Seasons Hotel Chicago. The live webcast of the presentation may be accessed by clicking on "William Blair 38th Annual Growth Stock Conference" under the investor relations section of the Company's website. Access the free research report on WAT now by signing up at:
www.wallstequities.com/registration/?symbol=WAT
West Pharmaceutical Services
Exton, Pennsylvania headquartered West Pharmaceutical Services Inc.'s shares gained 1.52%, closing the session at $96.75 with a total trading volume of 305,892 shares. The stock has gained 10.07% in the last month and 5.12% over the previous three months. Shares of the Company are trading 8.15% and 3.34% above their 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the US, Germany, France, Other European countries, and internationally, have an RSI of 70.68.
On May 24th, 2018, West Pharmaceutical Services announced that its Management team will present an overview of the Company's business at the Goldman Sachs 39th Annual Global Healthcare Conference on June 14th, 2018, at 10:00 a.m. PDT in Rancho Palos Verdes, California. A live audio webcast of the presentation and a copy of the presentation will be accessible on the Company's investors website. Are you already registered with Wall St. Equities? Do so now for free, and get the report on WST at:
www.wallstequities.com/registration/?symbol=WST
Ekso Bionics Holdings
Last Friday at the close, shares in Richmond, California headquartered Ekso Bionics Holdings Inc. recorded a trading volume of 315,316 shares. The stock ended the session 1.69% higher at $1.81. The Company's shares have advanced 12.42% in the past month and 52.10% over the past year. The stock is trading above its 50-day and 200-day moving averages by 11.58% and 9.99%, respectively. Furthermore, shares of Ekso Bionics, which designs, develops, and sells exoskeletons for use in the healthcare, industrial, and military markets in North America and the EMEA region, have an RSI of 64.57. Aspiring Member, please take a moment to register below for your free research report on EKSO at:
www.wallstequities.com/registration/?symbol=EKSO
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
https://wallstequities.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities
